Final - June 23, 2021
MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) Centers for Disease Control and Prevention Atlanta, Georgia 30329 June 23-25, 2021 PRESIDER/PRESENTER(s) Wednesday, June 23, 2021 11:00 Welcome & Introductions Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC) 11:30 Coronavirus Disease 2019 (COVID-19) Vaccines Introduction Dr. Matthew Daley (ACIP, WG Chair) Overview of myocarditis and pericarditis Dr. Matthew Oster (CDC/NCBDDD) Update on COVID-19 vaccine safety, including myocarditis after mRNA vaccines Dr. Tom Shimabukuro (CDC/NCEZID)
VaST assessment Dr. Grace Lee (ACIP, VaST Co-chair) 12:45 Break 1:00 COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion Dr. Megan Wallace (CDC/NCIRD)
Discussion 2:15 Break 2:30 Public Comment 3:00 Overview of data to inform recommendations for additional doses of COVID-19 Dr. Sara Oliver (CDC/NCIRD) vaccines Discussion 4:00 Adjourn
Thursday, June 24, 2021 10:00 Welcome & Introductions Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC) 10:30 Dengue Vaccine Introduction Dr. Wilbur Chen (ACIP, WG Co-Chair) Acceptability of dengue vaccine in Puerto Rico Dr. Ines Esquilin (University of Puerto Rico, School of Medicine) Implementation of dengue vaccine in Puerto Rico Dr. Iris Cardona (Department of Health, Puerto Rico) Dengue vaccine draft recommendations using the evidence to recommendation Dr. Gabriela Paz-Bailey (CDC/NCEZID) framework Dengue VFC Resolution Dr. Jeanne Santoli (CDC/NCIRD) 12:20 Break 12:30 Influenza Vaccines Introduction Dr. Keipp Talbot (ACIP, WG Chair) Flucelvax Quadrivalent (ccIIV4) Phase III Randomized Controlled Dr. Gregg Sylvester (Seqirus) Trial—Immunogenicity and Safety in Children 6 through 47 months Work group considerations and proposed recommendations for the 2021-22 Dr. Lisa Grohskopf (CDC/NCIRD) Influenza Season Updates to Influenza VFC Resolution Dr. Jeanne Santoli (CDC/NCIRD) 2:10 Break 2:20 Rabies Vaccines Introduction Dr. Sharon Frey (ACIP, WG Chair) Rabies immune globulin Dr. Agam Rao (CDC/NCEZID) Rabies post-exposure prophylaxis schedule Dr. Agam Rao (CDC/NCEZID) Rabies pre-exposure prophylaxis: GRADE/EtR summary Dr. Agam Rao (CDC/NCEZID) 3:40 Break 3:45 Public Comment 4:15 Break 4:20 Votes and VFC Votes Dengue Vaccine Dr. Gabriela Paz-Bailey (CDC/NCEZID) Dengue Vaccine (VFC) Dr. Jeanne Santoli (CDC/NCIRD) Influenza Vaccines Dr. Lisa Grohskopf (CDC/NCIRD) Influenza Vaccine (VFC) Dr. Jeanne Santoli (CDC/NCIRD) Rabies Vaccines Dr. Agam Rao (CDC/NCEZID) 5:15 Adjourn
page 1 of 2 Draft - June 21, 2021
Friday, June 25, 2021 10:00 Welcome & Introductions Dr. José Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary, CDC) 10:15 Zoster Vaccines Introduction Dr. Grace Lee (ACIP, WG Chair) Burden of herpes zoster in immunocompromised adults Dr. Tara Anderson (CDC/NCIRD) Use of recombinant zoster vaccine in immunocompromised populations: overview of Ms. Robyn Widenmaier (GSK) clinical program
11:05 Pneumococcal Vaccines Introduction Dr. Kathy Poehling (ACIP, WG Chair) Updates on epidemiology of invasive pneumococcal disease in U.S. adults Mr. Ryan Gierke (CDC/NCIRD) Cost effectiveness of PCV15 and PCV20 use in U.S. adults Dr. Charles Stoecker (Tulane University) GRADE for age-based PCV15 and PCV20 use in U.S. adults Ms. Jennifer Farrar (CDC/NCIRD) EtR summary of age-based PCV15 and PCV20 use in U.S. adults Dr. Miwako Kobayashi (CDC/NCIRD) Summary and Timeline Dr. Miwako Kobayashi (CDC/NCIRD) 1:00 Adjourn
Acronyms CDC Centers for Disease Control and Prevention CMS Centers for Medicare and Medicaid Services COVID-19 Coronavirus Disease 2019 EtR Evidence to Recommendations Framework FDA Food and Drug Administration GRADE Grading of Recommendations Assessment, Development and Evaluation HRSA Health Resources and Services Administration IHS Indian Health Service NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/DDID] NCIRD National Center for Immunization & Respiratory Diseases [of CDC/DDID] NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/DDID] NIAID National Institute of Allergy and Infectious Diseases OIDP Office of Infectious Disease and HIV/AIDS Policy PCV15 15-Valent Pneumococcal Conjugate Vaccine PCV20 20-Valent Pneumococcal Conjugate Vaccine SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 WG Work Group WHO World Health Organization VE Vaccine Effectiveness
page 2 of 2